lapatinib has been researched along with Heart Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Fu, H; Gao, Z; He, Q; Jin, Y; Luo, P; Pan, Z; Wang, X; Xu, B; Xu, Z; Yan, H; Yang, B; Yang, X; Zeng, Y; Zhang, X; Zhang, Y | 1 |
| Lind, P; Nearchou, A; Polyzos, NP; Valachis, A | 1 |
| Hoving, S; Russell, NS; Seemann, I; Song, JY; Stewart, FA; te Poele, JA | 1 |
| Azim, H; Azim, HA; Escudier, B | 1 |
| Altundag, K; Dogan, E; Ozer, N; Ozisik, Y; Petekkaya, I; Yorgun, H | 1 |
| Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
| Eniu, A | 1 |
4 review(s) available for lapatinib and Heart Diseases
| Article | Year |
|---|---|
Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Heart Diseases; Humans; Lapatinib; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2013 |
Trastuzumab versus lapatinib: the cardiac side of the story.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Heart Diseases; Humans; Lapatinib; Quinazolines; Trastuzumab | 2009 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Heart Diseases; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
1 trial(s) available for lapatinib and Heart Diseases
| Article | Year |
|---|---|
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Heart Diseases; Humans; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
3 other study(ies) available for lapatinib and Heart Diseases
| Article | Year |
|---|---|
PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Calcium; Cardiotoxicity; Endothelial Cells; Female; Heart Diseases; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice; Quinazolines; Rats; Receptor, ErbB-2; Trastuzumab | 2023 |
Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Cell Survival; Cells, Cultured; Coronary Vessels; Doxorubicin; Fibrosis; Heart Diseases; Humans; Lapatinib; Male; Mice; Mice, Inbred C57BL; Microvessels; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Pericardium; Quinazolines; Radiation Injuries, Experimental; Receptor, ErbB-2; Trastuzumab; Ventricular Function, Left | 2013 |
Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Heart; Heart Diseases; Humans; Incidence; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2012 |